Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

BACKGROUND: The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3(rd )or later-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lièvre, Astrid, Samalin, Emmanuelle, Mitry, Emmanuel, Assenat, Eric, Boyer-Gestin, Christine, Lepère, Céline, Bachet, Jean-Baptiste, Portales, Fabienne, Vaillant, Jean-Nicolas, Ychou, Marc, Rougier, Philippe
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761407/
https://www.ncbi.nlm.nih.gov/pubmed/19785749
http://dx.doi.org/10.1186/1471-2407-9-347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761407/
https://www.ncbi.nlm.nih.gov/pubmed/19785749
http://dx.doi.org/10.1186/1471-2407-9-347

Ejemplares similares